Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by stock analysts at UBS AG from a “neutral” rating to a “buy” rating in a report issued on Monday, TheFlyOnTheWall.com reports. In other Vertex Pharmaceuticals news, Director Bruce Sachs sold 8,300 shares of the stock on the open market in a transaction dated Monday, December 23rd. The shares were […]
Vertex Pharmaceuticals Upgraded by UBS AG to “Buy” (VRTX) is a post from: Zolmax
The post Vertex Pharmaceuticals Upgraded by UBS AG to “Buy” (VRTX) appeared first on Zolmax.